Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jul 25;28(3):309-315.
doi: 10.5603/RPOR.a2023.0033. eCollection 2023.

Palliative short-course radiotherapy (RAPASH study) in patients with rectal cancer

Marco Lupattelli  1 , Maria Valentina Tenti  2 , Serena Nucciarelli  2 , Luigina Graziosi  3 , Verena De Angelis  4 , Christian Fulcheri  5 , Cynthia Aristei  1
Affiliations

Palliative short-course radiotherapy (RAPASH study) in patients with rectal cancer

Marco Lupattelli et al. Rep Pract Oncol Radiother. .

Abstract

Background: Palliative radiation therapy (RT) is used to treat symptomatic rectal cancer although clinical benefits and toxicities are poorly documented. There is no consensus about the optimal RT regimen and clinical practice undergoes significant changes. Our aim was to evaluate the efficacy and toxicity of short-course (SC) RT in this setting of patients.

Materials and methods: Charts from patients with locally advanced disease not candidates for standard treatment or with symptomatic metastatic rectal cancer treated with SCRT (25 Gy/5 fractions in 5 consecutive days) were retrospectively reviewed. Clinical outcome measures were symptomatic response rate and toxicity.

Results: From January 2007 to December 2017, 59 patients (median age 80 years) received SCRT; 53 were evaluable. The median follow-up was 8 months (range, 1-70). Clinical response to RT for bleeding, pain and tenesmus was 100%, 95% and 89%, respectively. The compliance with the treatment was 100% and no patient experienced acute severe (≥ grade 3) toxicities. Median time to symptoms recurrence was 11 months (range 3-69). Globally, the median overall survival was 12 months.

Conclusions: SCRT is a safe and effective regimen in symptomatic rectal cancer and may be considered the regimen of choice for standard treatment in unfit patients.

Keywords: palliative radiation therapy; rectal cancer; short-course.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest None declared.

References

    1. Glimelius B, Cavalli-Björkman N. Metastatic colorectal cancer: current treatment and future options for improved survival. Medical approach--present status. Scand J Gastroenterol. 2012;47(3):296–314. doi: 10.3109/00365521.2012.640828. - DOI - PubMed
    1. Poultsides GA, Servais EL, Saltz LB, et al. Outcome of primary tumor in patients with synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment. J Clin Oncol. 2009;27(20):3379–3384. doi: 10.1200/JCO.2008.20.9817. - DOI - PMC - PubMed
    1. Cameron MG, Kersten C, Vistad I, et al. Palliative pelvic radiotherapy of symptomatic incurable prostate cancer - a systematic review. Radiother Oncol. 2014;110(1):55–60. doi: 10.1016/j.radonc.2013.08.008. - DOI - PubMed
    1. Lutz ST, Jones J, Chow E. Role of radiation therapy in palliative care of the patient with cancer. J Clin Oncol. 2014;32(26):2913–2919. doi: 10.1200/JCO.2014.55.1143. - DOI - PMC - PubMed
    1. Radu C, Berglund A, Påhlman L, et al. Short-course preoperative radiotherapy with delayed surgery in rectal cancer - a retrospective study. Radiother Oncol. 2008;87(3):343–349. doi: 10.1016/j.radonc.2007.11.025. - DOI - PubMed

LinkOut - more resources